|
1
|
Koch WM, Stafford E and Bajaj G: Cancer of
the oral cavity. Part A: General principles and managementHead and
neck cancer: A multidisciplinary approach. Harrison LB, Sessions RB
and Hong WK: 3rd. Lippincott Williams and Wilkins; Philadelphia,
PA: pp. 250–265. 2009
|
|
2
|
Feller L and Lemmer J: Oral squamous cell
carcinoma: Epidemiology, clinical presentation and treatment. J
Cancer Ther. 3:263–268. 2012. View Article : Google Scholar
|
|
3
|
Raff MC, Barres BA, Burne JF, Coles HS,
Ishizaki Y and Jacobson MD: Programmed cell death and the control
of cell survival: Lessons from the nervous system. Science.
262:695–700. 1993. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Wyllie AH, Kerr JF and Currie AR: Cell
death: The significance of apoptosis. Int Rev Cytol. 68:251–306.
1980.PubMed/NCBI
|
|
5
|
Kaufmann SH and Earnshaw WC: Induction of
apoptosis by cancer chemotherapy. Exp Cell Res. 256:42–49. 2000.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
King KL and Cidlowski JA: Cell cycle
regulation and apoptosis. Annu Rev Physiol. 60:601–617. 1998.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Boedefeld WM 2nd, Bland KI and Heslin MJ:
Recent insights into angiogenesis, apoptosis, invasion and
metastasis in colorectal carcinoma. Ann Surg Oncol. 10:839–851.
2003. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Maeshima Y, Colorado PC, Torre A, Holthaus
KA, Grunkemeyer JA, Ericksen MB, Hopfer H, Xiao Y, Stillman IE and
Kalluri R: Distinct antitumor properties of a type IV collagen
domain derived from basement membrane. J Biol Chem.
275:21340–21348. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Hamano Y and Kalluri R: Tumstatin, the NC1
domain of α3 chain of type IV collagen, is an endogenous inhibitor
of pathological angiogenesis and suppresses tumor growth. Biochem
Biophys Res Commun. 333:292–298. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Pasco S, Brassart B, Ramont L, Maquart FX
and Monboisse JC: Control of melanoma cell invasion by type IV
collagen. Cancer Detect Prev. 29:260–266. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Pasco S, Ramont L, Venteo L, Pluot M,
Maquart FX and Monboisse JC: n vivo overexpression of
tumstatin domains by tumor cells inhibits their invasive properties
in a mouse melanoma model. Exp Cell Res. 301:251–265. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Kawaguchi T, Yamashita Y, Kanamori M,
Endersby R, Bankiewicz KS, Baker SJ, Bergers G and Pieper RO: The
PTEN/Akt pathway dictates the direct alphaVbeta3-dependent
growth-inhibitory action of an active fragment of tumstatin in
glioma cells n vitro and n vivo. Cancer Res.
66:11331–11340. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Chung IS, Son YI, Ko YJ, Baek CH, Cho JK
and Jeong HS: Peritumor injections of purified tumstatin delay
tumor growth and lymphatic metastasis in an orthotopic oral
squamous cell carcinoma model. Oral Oncol. 44:1118–1126. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Jeon HK, Chang KH, Kim KI and Chung IS:
Functional expression of recombinant tumstatin in stably
transformed Drosophila melanogaster S2 cells. Biotechnol Lett.
25:185–189. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Alessandri G, Filippeschi S, Sinibaldi P,
Mornet F, Passera P, Spreafico F, Cappa PM and Gullino PM:
Influence of gangliosides on primary and metastatic neoplastic
growth in human and murine cells. Cancer Res. 47:4243–4247.
1987.PubMed/NCBI
|
|
16
|
Maeshima Y, Colorado PC and Kalluri R: Two
RGD-independent alpha v beta 3 integrin binding sites on tumstatin
regulate distinct anti-tumor properties. J Biol Chem.
275:23745–23750. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Maeshima Y, Sudhakar A, Lively JC, Ueki K,
Kharbanda S, Kahn CR, Sonenberg N, Hynes RO and Kalluri R:
Tumstatin, an endothelial cell-specific inhibitor of protein
synthesis. Science. 295:140–143. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Maeshima Y, Yerramalla UL, Dhanabal M, et
al: Extracellular matrix-derived peptide binds to alpha(v)beta (3)
integrin and inhibits angiogenesis. J Biol Chem. 276:31959–31968.
2001. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Monboisse JC, Garnotel R, Bellon G, Ohno
N, Perreau C, Borel JP and Kefalides NA: The alpha 3 chain of type
IV collagen prevents activation of human polymorphonuclear
leukocytes. J Biol Chem. 269:25475–25482. 1994.PubMed/NCBI
|
|
20
|
Li YJ, Sun LC, He Y, Liu XH, Liu M, Wang
QM and Jin XM: The anti-tumor properties of two tumstatin peptide
fragments in human gastric carcinoma. Acta Pharmacol Sin.
30:1307–1315. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Liu Y, Li J, Xu H, Zhang Y, Liu Y and Liu
X: Mitochondria-mediated tumstatin peptide-induced HepG2 cell
apoptosis. Int J Mol Med. 24:653–659. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
López-Hernández FJ, Ortiz MA and
Piedrafita FJ: The extrinsic and intrinsic apoptotic pathways are
differentially affected by temperature upstream of mitochondrial
damage. Apoptosis. 11:1339–1347. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Yin XM: Signal transduction mediated by
Bid, a pro-death Bcl-2 family proteins, connects the death receptor
and mitochondria apoptosis pathways. Cell Res. 10:161–167. 2000.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Maeshima Y, Manfredi M, Reimer C, Holthaus
KA, Hopfer H, Chandamuri BR, Kharbanda S and Kalluri R:
Identification of the anti-angiogenic site within vascular basement
membrane-derived tumstatin. J Biol Chem. 276:15240–15248. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Oliveira-Ferrer L, Wellbrock J, Bartsch U,
Penas EM, Hauschild J, Klokow M, Bokemeyer C, Fiedler W and Schuch
G: Combination therapy targeting integrins reduces glioblastoma
tumor growth through antiangiogenic and direct antitumor activity
and leads to activation of the pro-proliferative prolactin pathway.
Mol Cancer. 12:1442013. View Article : Google Scholar : PubMed/NCBI
|
